Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM77XQT)

Drug Name
NFX-179 Drug Info
Synonyms
Nedometinib; NFX-179; K5T4I78IYZ; 2252314-46-6; 2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide; 2-((2-Fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrolo(2,3-b)pyridine-3-carboxamide; UNII-K5T4I78IYZ; NFX179; SCHEMBL21979494; GTPL12872; Example 2 [US11161845B2]; HY-156625; CS-0886460; EN300-27122249; 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1-methylpyrrolo[2,3-b]pyridine-3-carboxamide
Indication
Disease Entry ICD 11 Status REF
Neurofibromatosis 1 LD2D.10 Phase 2 [1]
Cross-matching ID
PubChem CID
146585168
TTD Drug ID
DM77XQT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting ERK activator kinase (MEK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ARRY-162 DM1P6FR Melanoma 2C30 Approved [3]
HL-085 DMJDVCW Melanoma 2C30 Phase 1/2 [4]
RG7304 DMGFAVQ Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
GDC-0623 DMDY08K Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
BI 3011441 DMFJGUL Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
Pyridinone compound 1 DM2GR5Q N. A. N. A. Patented [8]
Quinazolines and azaquinazoline derivative 1 DME24BI N. A. N. A. Patented [8]
PMID28594589-Compound-TABLE3C2 DMVYG0U N. A. N. A. Patented [8]
Benzoheterocyclic compound 1 DM3K25J N. A. N. A. Patented [8]
Benzoimidazole derivative 1 DMUJFCK N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ERK activator kinase (MEK) TTZCRP3 NOUNIPROTAC Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04435665) A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of NFlection Therapeutics
3 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4 Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22(10):1551.
5 Clinical pipeline report, company report or official report of Roche.
6 Clinical pipeline report, company report or official report of Genentech (2011).
7 Clinical pipeline report, company report or official report of Boehringer Ingelheim.
8 MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.